Synosia Therapeutics Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson's Disease

Bookmark and Share

BASEL, Switzerland--(BUSINESS WIRE)--Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.

Back to news